ASCO 临床实践指南更新:多发性骨髓瘤中骨修饰药物的作用
推荐对需要系统治疗的活动性症状性多发性骨髓瘤患者(无论影像学是否有溶骨破坏或骨质疏松性椎体压缩骨折),每 3-4 周静脉给予帕米膦酸 90 mg(输注至少 2 小时)或唑来膦酸 4 mg(输注至少 15 分钟);地舒单抗在预防骨骼相关事件方面非劣于唑来膦酸,可作为替代选择。
要点
- 活动性症状性多发性骨髓瘤需系统治疗者,推荐每 3-4 周静脉帕米膦酸 90 mg 或唑来膦酸 4 mg。
- 地舒单抗预防骨骼相关事件非劣于唑来膦酸,肾毒性不良事件更少,可优先考虑。
- 骨修饰治疗持续至多 2 年;疾病缓解或稳定者可考虑减少给药频率。
核心结论
- 更新证据支持当前推荐:活动性症状性多发性骨髓瘤患者应接受骨修饰治疗。
- 地舒单抗预防骨骼相关事件非劣于唑来膦酸,且肾毒性不良事件更少,可优先选用。
研究设计与样本
- 指南更新小组通过检索 PubMed 和 Cochrane Library 进行靶向系统性文献综述。
- 检索范围包括随机对照试验、系统评价、荟萃分析、临床实践指南和观察性研究。
主要发现
- 更新证据支持当前关于骨修饰药物在多发性骨髓瘤中应用的推荐。
- 地舒单抗在预防骨骼相关事件方面非劣于唑来膦酸。
- 与唑来膦酸相比,地舒单抗相关的肾毒性不良事件更少。
关键数值与推荐
- 对需要系统治疗的活动性症状性多发性骨髓瘤患者(无论平片或其他影像学是否有溶骨破坏或骨质疏松性椎体压缩骨折证据),推荐每 3-4 周静脉给予帕米膦酸 90 mg(输注至少 2 小时)或唑来膦酸 4 mg(输注至少 15 分钟)。
- 地舒单抗在预防骨骼相关事件方面非劣于唑来膦酸,可作为替代选择;肾毒性不良事件更少,在此情况下可能优先选用。
- 建议临床医生考虑对已有肾功能损害的患者降低帕米膦酸初始剂量。
- 唑来膦酸未在严重肾功能损害患者中研究,不推荐用于此情况。
- 建议骨修饰治疗持续至多 2 年;对治疗有反应或疾病稳定者可考虑减少给药频率;持续使用由治疗医生根据持续骨骼并发症风险决定;疾病复发时应重新开始治疗。
临床怎么用
- 对适合的活动性症状性多发性骨髓瘤患者,选择帕米膦酸或唑来膦酸静脉给药,每 3-4 周一次。
- 地舒单抗可作为唑来膦酸的替代,尤其关注肾毒性时可能优先选用。
- 肾功能损害患者使用帕米膦酸需考虑降低初始剂量;严重肾功能损害不推荐唑来膦酸。
- 骨修饰治疗持续至多 2 年,缓解或稳定患者可减少给药频率,复发时重新治疗。
- 需关注下颌骨坏死相关措施(指南更新小组讨论了相关措施)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended. Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative. Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting. The update panel recommends that clinicians consider reducing the initial pamidronate dose in patients with preexisting renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The update panel suggests that bone-modifying treatment continue for up to 2 years. Less frequent dosing has been evaluated and should be considered in patients with responsive or stable disease. Continuous use is at the discretion of the treating physician and the risk of ongoing skeletal morbidity. Retreatment should be initiated at the time of disease relapse. The update panel discusses measures regarding osteonecrosis of the jaw. Additional information is available at www.asco.org/hematologic-malignancies-guidelines and www.asco.org/guidelineswiki .
引用
- Anderson K, Ismaila N, Flynn PJ, et al. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29341831. doi:10.1200/JCO.2017.76.6402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。